NewcelX Ltd.

NCEL

Healthcare|Biotechnology|CH

$2.72

-0.17 (-5.73%)

DCF Value

$0.18

Graham Number

$2.39

Cash / Share

$0.12

About

NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.

Stock Price

-34.5%(1Y)

-12.4%

-17.7%

-18.9%

YTD

+43.4%

-30.0%

-99.0%

-99.7%

Pipeline Summary

0 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Key Facts

Market Cap$1.2M

Employees4

CEORonen Twito

IPO DateOct 24, 2025

Beta0.93

52-Week Range$1.83 – $5.12

Avg Volume16,432

ExchangeNASDAQ

Websitenewcelx.net

Ownership

Float100.0%

Shares Outstanding0.5M

Recent Insider Trades

Samuel OlivierBUY

Apr 27, 2026114,545 shares @ $3.02

Samuel OlivierBUY

Apr 27, 202681,818 shares @ $2.75

Revel MichelBUY

Apr 27, 202654,545 shares @ $2.75

Revel MichelBUY

Apr 27, 202676,363 shares @ $3.02

Molakandov KfirOTHER

Mar 18, 202611,396 shares @ $7.62

Peers

BACKIMAC Holdings, Inc.

$378.00

BCTXWBriaCell Therapeutics Corp.

$1.7K

CELUCelularity Inc.

$24.7M

CEROCERo Therapeutics Holdings, Inc.

$214.9K

KTTAPasithea Therapeutics Corp.

$19.3M

NUWENuwellis, Inc.

$422.3K

OCEAOcean Biomedical, Inc.

$23.2K

PREPrenetics Global Limited

$270.0M

Recent News

NewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone Payments

Nov 4, 2026 · globenewswire.com

NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes

Sep 28, 2026 · globenewswire.com

Data last updated: Nov 9, 2026, 04:23 AM